In oncology we have successfully completed recruitment for the following trial – SarcoPET - MyxofibroSarcoma staging using PET-MRI: comparison to standard MRI

The new PET-MRI facility at Newcastle University will allow us to evaluate whether PET-MRI is superior at local staging of MFS compared to the standard MRI approach. This pilot study aimed to recruit patients with MFS to have a combined PET-MRI scan before their surgery in addition to any other MRI scan the patient may already have had. The results of the combined PET-MRI scan will be compared against those from PET alone, MRI alone and the removed tumour after surgery to see whether PET-MRI gives us more accurate information about the tumour and to see whether it would have helped the surgeon. We will also be looking to see if PET-MRI demonstrates disease elsewhere in the body (metastases).

It is anticipated that the pilot data will enable planning of a larger multicentre study to choose the best modality and techniques in order to optimise MFS tumour resection and staging.

The PET-MRI scanner is now also open to referrals from the Roche Graduate 2 trial which is looking at Gantenerumab (an investigational monoclonal antibody) for the treatment of early Alzheimer’s Disease (AD).